Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505310 · ClinicalTrials.gov registry record · NA
Biobehavioral Effects of Emotional Expression in Cancer
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 705
- Enrollment target
NCT00505310: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00505310 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 705 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505310, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 705 participants
- Enrollment target
Study Summary
The proposed study will assess the psychological and physiological benefits of an emotional expression intervention in patients with renal cancer. Patients will be randomly assigned to an emotional expression writing group or to a neutral writing group. This study will also evaluate the extent to which psychosocial factors mediate the intervention program and predict patients' recovery and adjustment to treatment. Potential mediators include level of cognitive processing, social networks/interactions, and sense of coherence and ability to find meaning in the illness experience. Specific objectives of the proposed research are: * To evaluate an emotional expression intervention in patients with renal cancer. Researchers will determine the extent to which an emotional expression writing-based intervention enhances adjustment during the first 12 months following diagnosis and treatment. Dimensions of adjustment will be assessed by examining indices of QOL, mental health, and stress (subjective symptoms of distress, perceived stress, and mood). * To determine the effects of an emotional expression writing-based intervention on immune function. The immune measures assessed in this study will include both general and autologous tumor-specific immune responses including cytotoxicity to K562 target cells; cytotoxicity to autologous tumor target cells; and functional assessment of type-1 and type-2 cytokines using autologous tumor and polyclonal stimulants. * To identify the psychosocial processes underlying the efficacy of the intervention.
Interventions
- BEHAVIORAL Questionnaire
- BEHAVIORAL Writing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2002-08-21 |
| Est. Completion | 2022-08-10 |
| Phase | NA |
What the finished NCT00505310 record still lists
NCT00505310 is an interventional study that assigns participants to a tested intervention. The registered 705 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Questionnaire is the first listed.
NCT00505310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00505310 about?
NCT00505310 is a clinical study titled "Biobehavioral Effects of Emotional Expression in Cancer". The proposed study will assess the psychological and physiological benefits of an emotional expression intervention in patients with renal cancer. Patients will be randomly assigned to an emotional expression writing group or to a neutral writing group. This study will also evaluate the extent to wh...
What is the current status of trial NCT00505310?
This trial is currently completed. It is a NA study. The enrollment target is 705 participants. The study started on 2002-08-21. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT00505310?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Writing (BEHAVIORAL).
Who is sponsoring clinical trial NCT00505310?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00505310's enrollment target sits among peer trials
705 148th of 2000 higher than 1,853 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI